中国肺癌杂志2026，Vol.29Issue(3)：200-207,8.DOI:10.3779/j.issn.1009-3419.2026.101.07
肠道真菌组在肺癌免疫治疗中的作用:机制、挑战与转化前景
Role of Gut Mycobiome in Lung Cancer Immunotherapy:Mechanisms,Challenges and Translational Prospects
王欣怡 1孙瑜 1刘敏 1何子轩 1曹文娇 1刘维英2
作者信息
- 1. 730000 兰州,兰州大学第一临床医学院
- 2. 730000 兰州,兰州大学第一医院呼吸与危重症一病区
- 折叠
摘要
Abstract
Lung cancer is one of the most common malignancies with the highest morbidity and mortality world-wide.Immune checkpoint inhibitors(ICIs)have significantly improved the prognosis of patients with advanced lung cancer,but more than half of patients derive limited benefit.The gut microbiota can regulate tumor immunity and ICIs efficacy via the gut-lung axis.Although accounting for a small proportion,the gut mycobiome exerts key immunomodulatory effects,yet relevant research lags far behind that of bacteria.This review systematically summarizes the clinical association between the gut mycobiome and lung cancer,clarifies the potential mechanisms by which the mycobiome and its metabolites influence ICIs ef-ficacy through immune regulation,metabolic modulation,and cross-kingdom interactions,and summarizes potential strategies including dietary intervention,fecal microbiota transplantation,and fungal targeting.It provides theoretical support for estab-lishing mycobiome-based predictive models,developing precise interventions,and improving the efficacy of ICIs.关键词
肠-肺轴/肺肿瘤/肠道真菌/免疫检查点抑制剂/生物标志物Key words
Gut-lung axis/Lung neoplasms/Gut mycobiome/Immune checkpoint inhibitors/Biomarkers引用本文复制引用
王欣怡,孙瑜,刘敏,何子轩,曹文娇,刘维英..肠道真菌组在肺癌免疫治疗中的作用:机制、挑战与转化前景[J].中国肺癌杂志,2026,29(3):200-207,8.
